

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Rizzieri, et al.
Serial No.: 10/008,062
Filed: October 19, 2001
For: ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA

Group Art Unit: 1619

June 5, 2002

RECEIVED

JUN 20 2002

Commissioner for Patents
Washington, DC 20231


TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a Supplemental Form PTO-1449 listing several documents cited in the International Search Report for the corresponding International Application Number PCT/US01/46104. Each document listed on the attached PTO-1449 was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. A copy of each document, including the Search Report, is enclosed. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. The Commissioner is hereby authorized to charge any additional fee, which may be required, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on June 5, 2002.



Vickie Diane Prior

Date of Signature: June 5, 2002

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/008,062
				Filing Date	October 19, 2001
				First Named Inventor	David Rizzieri
				Group Art Unit	1619
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	5405.252



RECEIVED

JUN 20 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,624,659		Bigner et al.	4/29/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	2	Chilosi, Marco, et al., <i>Constitutive Expression of Tenascin in T-Dependent Zones of Human Lymphoid Tissues</i> , <i>American Journal of Pathology</i> , Vol. 143, No. 5, pp. 1348-1355 (November 1993)		
	3	Rizzieri, D. A., et al., <i>Markers of Angiogenesis, Factor VIII and Tenascin, Correlate with Disease Activity in Patients with Non-Hodgkin's Lymphoma</i> , Abstract, <i>Blood</i> , Vol. 94, No. 10, Part 2, Supp. 1, page 4339 (15 November 1999)		
	4	Rizzieri, D.A., et al., <i>Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma</i> , Abstract, <i>Blood</i> , Vol. 98, No. 11, Part 2, pp. 247b (16 November 2001)		
	5	International Search Report, International Application No. PCT/US01/46104		

**COPY OF PAPERS
ORIGINALLY FILED**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.